Search

Circulating proteomes provide a snapshot of the physiological state of a human organism responding to pathogenic challenges and drug interventions. The outcomes of patients with COVID-19 and acute respiratory distress syndrome triggered by the SARS-CoV2 virus remain uncertain. Tocilizumab is an anti-interleukin-6 treatment that exerts encouraging clinical activity by controlling the cytokine storm and improving respiratory distress in patients with COVID-19. We investigate the biological determinants of therapeutic outcomes after tocilizumab treatment. Overall, 28 patients hospitalized due to severe COVID-19 who were treated with tocilizumab intravenously were included in this study. Sera were collected before and after tocilizumab, and the patient’s outcome was evaluated until day 30 post-tocilizumab infusion for favorable therapeutic response to tocilizumab and mortality. Hyperreaction monitoring measurements by liquid chromatography–mass spectrometry-based proteomic analysis with data-independent acquisition quantified 510 proteins and 7019 peptides in the serum of patients. Alterations in the serum proteome reflect COVID-19 outcomes in patients treated with tocilizumab. Our results suggested that circulating proteins associated with the most significant prognostic impact belonged to the complement system, platelet degranulation, acute-phase proteins, and the Fc-epsilon receptor signaling pathway. Among these, upregulation of the complement system by activation of the classical pathway was associated with poor response to tocilizumab, and upregulation of Fc-epsilon receptor signaling was associated with lower mortality.

En oncologie, l’utilisation des tests génomiques représente un élément majeur pour faciliter la mise en place d’une médecine de précision. Toutefois, les recommandations actuelles ne précisent pas toujours l’indication et l’intérêt de ces tests en fonction du type de cancer. Une démarche de consensus national de type Delphi-modifié a été mise en place afin de fournir un avis d’experts sur l’utilisation des tests génomiques en pratique clinique en France. Quatre groupes d’experts représentant les thématiques d’intérêt ont été définis : carcinome bronchique non à petites cellules (CBNPC), cancer du sein, mélanome et carcinome de primitif inconnu (CUP). Dans chaque groupe, des assertions ont été formulées par un référent (8, 5, 7 et 6, respectivement) et soumises au vote de cinq cotateurs impliqués dans la prise en charge de ces cancers, sur une échelle de 1 (pas du tout d’accord) à 9 (tout à fait d’accord). Le consensus était obtenu lorsque 75 % des votes étaient supérieurs à sept. En cas de désaccord, les cotateurs étaient invités à justifier leurs votes. Au total, 24 assertions ont obtenu un consensus après deux à quatre tours de vote selon le groupe. Alors que les spécialistes préconisent d’utiliser les tests génomiques en routine dans la prise en charge diagnostique des CBNPC et des CUPs, ils ne recommandent pas la systématisation de ces tests pour le cancer du sein et le mélanome. Néanmoins, l’accès à l’innovation en France pourrait prochainement lever certaines barrières et permettre une plus grande standardisation du screeningmoléculaire large en oncologie.

Brigatinib is a potent next-generation ALK tyrosine kinase inhibitor approved for treatment-naive and crizotinib-refractory advanced ALK-positive (ALK+) NSCLC. We evaluated brigatinib after other next-generation ALK tyrosine kinase inhibitors.

La chirurgie est le traitement le plus fréquent pour les tumeurs solides. Présentant des spécificités et des techniques propres à chaque organe, elle est le plus souvent associée à des thérapies conventionnelles ou ciblées aux effets indésirables conséquents. Les patients qui en bénéficient présentent eux-aussi des caractéristiques singulières, telles que des facteurs de risque et des addictions à maîtriser, le besoin d’une préhabilitation, un accès aux voies aériennes complexe ou encore une douleur difficile à contrôler. Bien que nécessaire à la rémission ou à la reconstruction de séquelles esthétiques, la chirurgie est paradoxalement immunodépressive. L’inflammation, la douleur et le stress glucocorticoïde peropératoire affectent la réponse immune antitumorale et la manipulation directe de la tumeur favorise la dissémination des cellules cancéreuses. Il semble nécessaire de favoriser une prise en charge périopératoire qui pourrait renforcer les effecteurs du système immunitaire et diminuer les cellules tumorales résiduelles responsables des récidives métastatiques (immunonutrition, chirurgie mini-invasive, contrôle de la douleur…). La publication de travaux précliniques démontrant les mécanismes par lesquels les agents d’anesthésie pourraient avoir une activité immunomodulatrice laisse suggérer que le choix des produits d’anesthésie pourrait jouer un rôle sur le pronostic oncologique. Connaître les caractéristiques des différents traitements médicaux et chirurgicaux anti-cancéreux, maîtriser les facteurs périopératoires immunosuppresseurs et privilégier les produits d’anesthésie anti-tumoraux sont des pratiques encouragées afin d’optimiser la rémission et éviter les rechutes. Le but de cette mise au point est de donner un aperçu de ces particularités qui pourraient utilement faire l’objet d’un enseignement spécifique en onco-anesthésie inexistant à ce jour.

Study objectives: To compare the quality of non-small cell lung cancer (NSCLC) surgical care with patient satisfaction. Design: Prospective study. Setting: Academic hospital departments of thoracic oncology and surgery. Patients [...]

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila(Akk) was associated with clinical benefit of ICI in patients with NSCLC or kidney cancer. In the current study, we performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n= 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk. Baseline stool Akk was associated with increased objective response rates and overall survival in multivariate analyses, independent of PD-L1 expression, antibiotics, and performance status. Intestinal Akk was accompanied by a richer commensalism, including Eubacterium halliiand Bifidobacterium adolescentis, and a more inflamed tumor microenvironment in a subset of patients. However, antibiotic use (20% of cases) coincided with a relative dominance of Akk above 4.8% accompanied with the genus Clostridium, both associated with resistance to ICI. Our study shows significant differences in relative abundance of Akk that may represent potential biomarkers to refine patient stratification in future studies.

Dabrafenib plus trametinib was found to have robust antitumor activity in patients with BRAFV600E-mutant metastatic NSCLC (mNSCLC). We report updated survival analysis of a phase 2 study (NCT01336634) with a minimum of 5-year follow-up and updated genomic data.

Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus–host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Cancer patients with a prolonged SARS-CoV-2 RNA detection exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of nonconventional monocytes, and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T-helper cells, and non-naive Granzyme B+FasL+, EomeshighTCF-1high, PD-1+CD8+Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity, and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long-term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.

We report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months of median follow-up with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP) in chemotherapy-naive patients with metastatic nonsquamous NSCLC in the phase 3 IMpower150 study (NCT02366143).

In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.

The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient subgroups.

We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC.

Background: Pembrolizumab, a humanized immunoglobulin monoclonal antibody directed against the programmed cell death 1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials.Aim: To investigate the efficacy and safety of first-line pembrolizumab for patients with non-small cell lung cancers (NSCLCs) in clinical practice.Methods: In this observational monocentric retrospective study, 38 patients with PD-L1 >50% were enrolled between November 2017 and November 2018.Results: The global median overall survival was 11.08 months (95% confidence interval [CI], 5.98–not reached) and the global median progression-free survival was 6 months (95% CI, 3–not reached). In the univariate analysis, clinical performance status score and the development of immune-related adverse events were the only 2 clinical factors significantly correlated with overall survival.Conclusion: The results of the present study suggest that pembrolizumab seems less effective in the real-life population than in the pivotal clinical trials in patients with NSCLC but remains an effective treatment option for patients with NSCLC. Longer follow-up is needed.

The phase 2 POPLAR and phase 3 OAK studies of the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p= 0.04 and 0.0003, respectively). Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports the final overall survival (OS) and safety findings from both trials.

L’immunothérapie par inhibiteurs de points de contrôle immunitaires (ICI) a récemment révolutionné la prise en charge de nombreux cancers solides. Les ICI ont pour but de restaurer l’action du lymphocyte T sur la cellule tumorale en inhibant des signaux de régulation négative impliqués dans la cancérogenèse. L’utilisation en routine des ICI depuis quelques années a permis d’en identifier le profil de tolérance. Les effets secondaires sont immuno-médiés, secondaires à la stimulation du système immunitaire induite par le traitement. Ces effets secondaires restent rares en comparaison avec ceux observés avec les chimiothérapies standards mais sont potentiellement graves, et peuvent remettre en cause la poursuite d’un traitement efficace. De nombreuses nouvelles immunothérapies sont en cours de développement, dont les mécanismes d’action sont variés, mais toujours dans le but de restaurer la réponse immunitaire anti-tumorale. De nouvelles molécules impliquent de nouveaux profils de tolérance, d’autant plus qu’un grand nombre d’essais cliniques évaluent des associations d’immunothérapies. Étant donné la multitude de traitements à l’étude, la connaissance et la prise en charge de ces toxicités sera un enjeu majeur dans le choix des nouvelles séquences thérapeutiques de nombreuses pathologies tumorales. En effet, malgré le pronostic sombre des types tumoraux concernés par ces innovations, l’amélioration progressive des données de survie dans ces pathologies entraîne une exposition au traitement de plus en plus longue. La tolérance et la qualité de vie pendant le traitement deviennent donc des arguments majeurs de la décision thérapeutique.

Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify undetermined nodules detected on LDCT. We previously showed that circulating tumour cells (CTCs) could be detected, using the isolation by size of epithelial tumour cell technique (ISET), long before the cancer was diagnosed radiologically. We aimed to test whether CTCs could be used as a biomarker for lung cancer screening.

In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class of agents. The reactivation of host antitumor immune response offers the potential for long-term survival benefit in a portion of patients with thoracic malignancies.

The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications without compromising cancer outcomes. Since COVID-19 is a novel disease, guidance by scientific evidence is often unavailable, and impactful decisions are inevitably made on the basis of expert opinions. Here we report how the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations ‘pandemic proof’. We identify and discuss many commonalities, but also important local differences, and pinpoint critical research priorities to enable evidence-based remodeling of cancer care during the COVID-19 pandemic. Also, we discuss how the current situation offers a unique window of opportunity for assessing the effects of de-escalating anticancer regimens, which may fast-forward the development of more-refined and less-toxic treatments. By sharing our joint experiences, we offer a roadmap for proceeding and aim to mobilize the global research community to generate the data that are critically needed to offer the best possible care to patients.

Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype with poor prognosis. As such, our study sought to retrospectively assess the efficacy of ICI in SC.

MET proto-oncogene (MET)exon 14 splice site (METex14) mutations were recently described in NSCLC and has been reported to correlate with efficacy of MET tyrosine kinase inhibitors. High diversity of these alterations makes them hard to detect by DNA sequencing in clinical practice. Because METex14 mutations induce increased stabilization of the MET receptor, it is anticipated that these mutations are associated with MET overexpression. We aim to determine whether NSCLC with high MET overexpression could define a subset of patients with a high rate of METex14 mutations.

KRASmutation is the most frequent molecular alteration found in advanced NSCLC; it is associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICIs), and data about its efficacy in patients with KRAS-mutant NSCLC are discordant. This study assessed the routine efficacy of ICIs in advanced KRAS-mutant NSCLC.

In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.

This phase II study evaluated the efficacy and safety of the pan-cyclin–dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease SCLC.

Les biobanques tumorales sont sollicitées dans le cadre du développement de la recherche translationnelle et clinique en cancérologie. Elles participent à l’évaluation puis à la validation des biomarqueurs à visée diagnostique, pronostique ou prédictive. L’évolution progressive de ces structures a permis de professionnaliser leur fonctionnement et de les identifier comme des rouages incontournables en oncologie par les acteurs du monde académique et industriel. Les progrès technologiques et thérapeutiques modifient l’impact et le fonctionnement de ces biobanques, ces dernières devant relever plusieurs défis afin notamment d’être pérennisées. Parmi les enjeux, l’intégration des données (cliniques et biologiques) de plus en plus complexes et massives associées aux échantillons biologiques, conduit à avoir une réflexion urgente pour une organisation optimisée des biobanques en France. Le but est d’être attractif aux yeux des partenaires face à la compétition internationale. Cette revue aborde rapidement les principales évolutions actuelles des biobanques, puis les défis actuels et futurs, et enfin la place que le pathologiste peut jouer dans ces nouveaux challenges de l’oncologie.

Nivolumab, a fully human immunoglobulin monoclonal antibody inhibiting the programmed cell death protein‐1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. The aim of the present study was to investigate the efficacy and safety of nivolumab for pretreated patients with non-small cell lung cancers in clinical practice. In this observational monocentric retrospective study, 98 patients were enrolled between February 2015 and February 2016. The global median overall survival was 6.34 months (95% confidence interval (CI) : 4.11–10.88) and the global median progression free survival was 1.84 months (95% CI: 1.68–2.73). In the univariate analysis, clinical performance status score was the only factor significantly correlated with overall survival. The safety profile of nivolumab is consistent with that described in prior studies, with only 7% undesirable effects requiring the discontinuation of treatment. The results of the present study demonstrate that nivolumab affords clinical efficacy and manageable tolerability in patients with non-small cell lung cancers.

Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK study of atezolizumab (anti–programmed death-ligand 1) versus docetaxel in advanced NSCLC, overall survival (OS) benefit with atezolizumab was observed in the overall patient population, without improvement in objective response rate (ORR) or progression-free survival (PFS). We examine the benefit-risk of atezolizumab treatment beyond progression (TBP).

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests — such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements — are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.

The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second- or third-line treatment in patients with advanced NSCLC in the primary (n = 850) and secondary (n = 1225) efficacy populations of the randomized phase III OAK study (respectively referred to as the intention-to-treat [ITT] 850 [ITT850] and ITT1225) at an updated data cutoff were assessed.

To evaluate diagnostic impact of routinely use of respiratory gated (RG) 18FDG PET/CT to distinguish benign and malignant lung nodules.

In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC.

ABSTRACTIntroduction: Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC. Other notable PD-L1 inhibitors under development include avelumab and durvalumab.Areas covered: This article reviews literature on durvalumab development, from the preclinical data to the results of phase III clinical trials, whether published or presented at international scientific conferences. Ongoing clinical trials were also reviewed.Expert opinion: Early phase trials of durvalumab monotherapy (and in combination) have demonstrated activity in advanced NSCLC patients and it has demonstrated a good safety profile. The authors believe that durvalumab will likely play an important role in future treatment strategies for NSCLC. The PACIFIC trial assessing durvalumab after standard chemoradiotherapy for locally advanced NSCLC has already met its primary endpoint and the potential of durvalumab will be reinforced if phase III randomized studies of first-line (MYSTIC trial) and second or subsequent (ARCTIC trial) lines of therapy demonstrate superiority over the current standard of care.

Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses.

Tobacco-related NSCLC is associated with reduced survival and greater genomic instability. Veliparib, a potent poly(adenosine diphosphate–ribose) polymerase inhibitor, augments platinum-induced DNA damage. A phase 2 trial of untreated advanced NSCLC showed a trend for improved outcomes (hazard ratio [HR] = 0.80, 95% confidence interval: 0.54–1.18, p = 0.27 for overall survival and HR = 0.72, 95% CI: 0.45–1.15, p = 0.17 for progression-free survival) when veliparib was added to carboplatin/paclitaxel. Here we report an exploratory analysis by smoking history.

Little is known about the prevalence, prognosis, and response to treatment of advanced NSCLC harboring multiple genomic alterations.

Les métastases osseuses représentent la cause la plus fréquente de douleur liée au cancer, diminuant la qualité de vie des patients et pouvant mettre en jeu le pronostic vital. Leur prise en charge doit être pluridisciplinaire, devant la multiplicité des options thérapeutiques et la diversité des localisations métastatiques. L’objectif de ce travail est de proposer un algorithme décisionnel rationnel dans la stratégie thérapeutique des localisations osseuses secondaires. Les médicaments anti-résorptifs à l’action systémique, la chirurgie, la radiothérapie classique ou stéréotaxique, ainsi que les techniques nouvelles de radiologie interventionnelle sont autant d’options qui peuvent être utilisées seules ou associées. Elles ont prouvé leurs bénéfices en termes de traitement symptomatique, améliorant la qualité de vie. Leurs indications diffèrent en fonction du site tumoral (os longs vs os courts, porteurs vs non-porteurs), de la symptomatologie (douleur, atteinte neurologique) et de la présence de complications (essentiellement fracturaires). Les innombrables présentations lésionnelles nous ont conduits à proposer cet algorithme décisionnel, afin de proposer la meilleure prise en charge pour chaque patient.

The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFRmutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation.

This two-part study evaluated trametinib, a MEK1/2 inhibitor, in combination with anticancer agents. Inhibition of MEK, a downstream effector of KRAS, demonstrated preclinical synergy with chemotherapy in KRAS-mutant NSCLC cell lines. Part 1 of this study identified recommended phase 2 doses of trametinib combinations. Part 2, reported herein, evaluated the safety, tolerability, pharmacokinetics, and efficacy of trametinib combinations in patients with NSCLC with and without KRASmutations.

Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.

Preclinical evaluation of bintrafusp alfa (BA) combined with radiotherapy revealed greater antitumor effects than BA or radiotherapy alone. In a phase 1 study, BA exhibited encouraging clinical activity in patients with stage IIIB/IV NSCLC who had received previous treatment.

We report the primary analysis from JAVELIN Lung 100, a phase 3 trial comparing avelumab (anti⁠–programmed death-ligand 1 [PD-L1]) versus platinum-based doublet chemotherapy as first-line treatment for PD-L1–positive (+) advanced NSCLC.

Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a human immunoglobulin G1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1), has exhibited clinical activity in a phase 1 expansion cohort of patients with PD-L1–high advanced NSCLC.

Dual immune checkpoint blockers regimen represents a standard first-line therapy in unresectable pleural mesothelioma (PM). Novel combination strategies, including immune checkpoint blockers and antiangiogenic drugs, are currently under investigation in this setting. We aimed to assess the efficacy of the chemoimmunotherapy combination by reference to literature evidence.

Nearly 1% to 2% of NSCLCs harbor RETfusions. Characterization of this rare population is still incomplete.

The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility and effects on outcomes of this policy are unknown. We aimed to assess the characteristics, molecular profiles, and clinical outcomes of patients who were screened during a 1-year period by a nationwide programme funded by the French National Cancer Institute.